<div id="readability-page-1"><div> <p>Health-care companies rose amid optimism about obesity-drug demand.</p> <p>   Shares of Novo Nordisk rose after the U.S. Food and Drug Administration approved the first GLP-1 weight-loss pill, a tablet formulation of the Danish company's drug branded as both Ozempic and Wegovy. The availability of pills for the medications that had already seen high demand in injection form is anticipated to bolster demand for the glucagon-like peptide inhibitors. </p> <p>   Shares of some other obesity-drug makers, including Viking Therapeutics, rose in sympathy. </p> <p>   A Baltimore city jury ordered Johnson &amp; Johnson to pay over $1.5 billion in a lawsuit that alleged the company's talc-based personal products gave a Maryland woman cancer. </p> <pre></pre> <p>   Write to Rob Curran at rob.curran@dowjones.com </p> <p>   (END) Dow Jones Newswires</p> <p>   December 23, 2025 18:13 ET (23:13 GMT)</p><p>Copyright (c) 2025 Dow Jones &amp; Company, Inc.</p></div></div>

诺和诺德公司

Viking治疗

<p>医疗保健股票因对肥胖药物需求的乐观情绪而上涨，诺和诺德公司的股票在其 GLP-1 减肥药获得 FDA 批准后上涨。预计该药物将增加对类胰高血糖素肽抑制剂的需求。其他肥胖药物制造商的股票，如 Viking Therapeutics，也有所上涨。此外，强生公司被判支付超过 15 亿美元的赔偿金，因其滑石粉产品被指控导致癌症</p>

医疗保健板块上涨，诺和诺德公司股价上升——医疗保健综述